{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:52:06Z","timestamp":1649047926390},"reference-count":14,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.19029","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T22:04:46Z","timestamp":1589321086000},"page":"37-40","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of salvage therapy with MTX-HOPE for elderly patients with                    heavily pretreated non-Hodgkin\u2019s lymphoma"],"prefix":"10.3960","volume":"60","author":[{"given":"Akiko","family":"Fukunaga","sequence":"first","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shojiro","family":"Inano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Takiuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyo","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital The Tazuke Kofukai                            Medical Research Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Coiffier                            B,                                Thieblemont                            C, Van                                Den Neste                            E                    <i>et al.<\/i> Long-term outcome of patients in the LNH-98.5 trial, the                    first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in                    DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood.                    2010; 116: 2040-2045.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hiddemann                            W,                                Kneba                            M,                                Dreyling                            M                    <i>et al.<\/i> Frontline therapy with rituximab added to the                    combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)                    significantly improves the outcome for patients with advanced-stage follicular                    lymphoma compared with therapy with CHOP alone: results of a prospective                    randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106:                    3725-3732.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Coiffier                            B,                                Lepage                            E,                                Bri\u00e8re                            J                    <i>et al.<\/i> CHOP chemotherapy plus rituximab compared with CHOP                    alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.                    2002; 346: 235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Salles                            G,                                Seymour                            JF,                                Offner                            F                    <i>et al.<\/i> Rituximab maintenance for 2 years in patients with high                    tumour burden follicular lymphoma responding to rituximab plus chemotherapy                    (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377: 42-51.","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nastoupil                            LJ,                                Sinha                            R,                                Byrtek                            M                    <i>et al.<\/i> The use and effectiveness of rituximab maintenance in                    patients with follicular lymphoma diagnosed between 2004 and 2007 in the United                    States. Cancer. 2014; 120: 1830-1837.","DOI":"10.1002\/cncr.28659"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Jaeger                            U,                                Trneny                            M,                                Melzer                            H                    <i>et al.<\/i>. Rituximab maintenance for patients with aggressive                    B-cell lymphoma in first remission: results of the randomized NHL13 trial.                    Haematologica. 2015; 100: 955-963.","DOI":"10.3324\/haematol.2015.125344"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Bergman                            AM,                                Pinedo                            HM,                                Talianidis                            I                    <i>et al.<\/i> Increased sensitivity to gemcitabine of P-glycoprotein                    and multidrug resistance-associated protein-overexpressing human cancer cell                    lines. Br J Cancer. 2003; 88: 1963-1970.","DOI":"10.1038\/sj.bjc.6601011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Gopal                            AK,                                Press                            OW,                                Shustov                            AR                    <i>et al.<\/i> Efficacy and safety of gemcitabine, carboplatin,                    dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a                    prospective multi-center phase II study by the Puget Sound Oncology Consortium.                    Leuk Lymphoma. 2010; 51: 1523-1529.","DOI":"10.3109\/10428194.2010.491137"},{"key":"9","unstructured":"9 Ohnishi                            K. [Oral                    antitumor drugs for hematological malignancies]. Gan To Kagaku Ryoho. 1999; 26:                    295-300."},{"key":"10","unstructured":"10 Tsunoda                            S,                                Kobayashi                            H,                                Inoue                            K                    <i>et al.<\/i> [MTX-HOPE (methotrexate, hydrocortisone, vincristine,                    sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or                    refractory non-Hodgkin\u2019s lymphoma]. Gan To Kagaku Ryoho. 2007; 34:                    885-889."},{"key":"11","unstructured":"11 Kano                            Y,                                Ohnuma                            T,                                Okano                            T,                                Holland                            JF. Effects of                    vincristine in combination with methotrexate and other antitumor agents in human                    acute lymphoblastic leukemia cells in culture. Cancer Res. 1988; 48:                    351-356."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ohno                            R,                                Masaoka                            T,                                Shirakawa                            S                    <i>et al.<\/i> Treatment of adult T-cell leukemia\/lymphoma with MST-16,                    a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). Cancer.                    1993; 71: 2217-2221.","DOI":"10.1002\/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Okamoto                            T,                                Nishimura                            Y,                                Yamada                            S                    <i>et al.<\/i> Long-term administration of oral low-dose topoisomerase                    II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin\u2019s                    lymphoma. Acta Haematol. 2000; 104: 128-130.","DOI":"10.1159\/000039746"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Swift                            LP,                                Cutts                            SM,                                Nudelman                            A                    <i>et al.<\/i> The cardio-protecting agent and topoisomerase II                    catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated                    cytotoxicity. Cancer Chemother Pharmacol. 2008; 61: 739-749.","DOI":"10.1007\/s00280-007-0528-2"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/2\/60_19029\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T04:28:24Z","timestamp":1592627304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/2\/60_19029\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.19029","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}